TY - JOUR
T1 - Results of radiation therapy for uterine cervical cancer using high dose rate remote after loading system
AU - Ogawa, Yoshihiro
AU - Nemoto, Kenji
AU - Kakuto, Yoshihisa
AU - Ariga, Hisanori
AU - Matsushita, Haruo
AU - Takeda, Ken
AU - Takahashi, Chiaki
AU - Gallardo, Britton
AU - Richard, Keith
AU - Takai, Yoshihiro
AU - Yamada, Shogo
PY - 2003/4/1
Y1 - 2003/4/1
N2 - In Japan, radiotherapy with high dose rate remote after loading system (HDR-RALS) for intracavitary brachytherapy is the standard treatment for more than 30 years. This report showed the usefulness of HDR-RALS for uterine cervical cancer. From 1980 through 1999, 442 patients with uterine cervical cancers (stage I: 66, stage II: 161, stage III: 165, stage IV: 50) were treated. Radiotherapy was performed both external teletherapy and HDR-RALS. Overall survival rate at 5 years was 60.2%. The 5-year actuarial incidence of all complications was 16.4%. The 5-year actuarial incidence of all complications in cases treated with the sum doses of whole pelvic irradiation (without central shield) and RALS up to 49 Gy, 50 to 59 Gy or larger doses were 7.5%, 11.0% and 25.2%, respectively. Radiation therapy using HDR-RALS was very effective. While the dose of whole pelvic irradiation was increased, the actuarial incidence of all complications was increased.
AB - In Japan, radiotherapy with high dose rate remote after loading system (HDR-RALS) for intracavitary brachytherapy is the standard treatment for more than 30 years. This report showed the usefulness of HDR-RALS for uterine cervical cancer. From 1980 through 1999, 442 patients with uterine cervical cancers (stage I: 66, stage II: 161, stage III: 165, stage IV: 50) were treated. Radiotherapy was performed both external teletherapy and HDR-RALS. Overall survival rate at 5 years was 60.2%. The 5-year actuarial incidence of all complications was 16.4%. The 5-year actuarial incidence of all complications in cases treated with the sum doses of whole pelvic irradiation (without central shield) and RALS up to 49 Gy, 50 to 59 Gy or larger doses were 7.5%, 11.0% and 25.2%, respectively. Radiation therapy using HDR-RALS was very effective. While the dose of whole pelvic irradiation was increased, the actuarial incidence of all complications was increased.
KW - Brachytherapy
KW - Radiotherapy
KW - RALS
KW - Uterine cervical cancer
UR - http://www.scopus.com/inward/record.url?scp=10744233870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744233870&partnerID=8YFLogxK
U2 - 10.1620/tjem.199.229
DO - 10.1620/tjem.199.229
M3 - Article
C2 - 12857063
AN - SCOPUS:10744233870
SN - 0040-8727
VL - 199
SP - 229
EP - 238
JO - Tohoku Journal of Experimental Medicine
JF - Tohoku Journal of Experimental Medicine
IS - 4
ER -
